Lead Product(s) : OQL051
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OQL051 sia first-in-disease, oral, gut-restricted CDK4/6 inhibitor – is designed to prevent the development of CID in patients receiving cytotoxic chemotherapies. The drug works by temporarily arresting the rapidly dividing intestinal mucosal cells in ...
Product Name : OQL051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : OQL051
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SMP-100
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First randomized, double-blinded, placebo-controlled Phase I clinical trial to investigate the safety and pharmacokinetics after oral administration of SMP-100 in healthy volunteers.
Product Name : SMP-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : SMP-100
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable